Anterogen.Co.Ltd
Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of stem cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn's fistula; Queencell, a stromal vascular fraction used for the regen… Read more
Anterogen.Co.Ltd - Asset Resilience Ratio
Anterogen.Co.Ltd (065660) has an Asset Resilience Ratio of 46.08% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Anterogen.Co.Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Anterogen.Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩42.13 Billion | 46.08% |
| Total Liquid Assets | ₩42.13 Billion | 46.08% |
Asset Resilience Insights
- Very High Liquidity: Anterogen.Co.Ltd maintains exceptional liquid asset reserves at 46.08% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Anterogen.Co.Ltd Industry Peers by Asset Resilience Ratio
Compare Anterogen.Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AGP Ltd
KAR:AGP |
Pharmaceuticals | 0.71% |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 4.82% |
|
DongKoo Bio&Pharma Co. Ltd
KQ:006620 |
Pharmaceuticals | 4.28% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Sam-A Pharm. Co. Ltd
KQ:009300 |
Pharmaceuticals | 34.37% |
|
Kyung Dong Pharmaceutical Co. Ltd
KQ:011040 |
Pharmaceuticals | 5.22% |
|
WooGene B&G Co. Ltd
KQ:018620 |
Pharmaceuticals | 3.35% |
|
Oscotec Inc
KQ:039200 |
Pharmaceuticals | 61.00% |
Annual Asset Resilience Ratio for Anterogen.Co.Ltd (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Anterogen.Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 32.88% | ₩38.17 Billion | ₩116.08 Billion | +0.13pp |
| 2023-12-31 | 32.75% | ₩48.95 Billion | ₩149.43 Billion | -12.33pp |
| 2022-12-31 | 45.09% | ₩55.97 Billion | ₩124.13 Billion | +1.92pp |
| 2021-12-31 | 43.17% | ₩59.01 Billion | ₩136.70 Billion | -7.70pp |
| 2020-12-31 | 50.87% | ₩47.92 Billion | ₩94.20 Billion | -8.27pp |
| 2019-12-31 | 59.14% | ₩50.03 Billion | ₩84.59 Billion | +9.02pp |
| 2018-12-31 | 50.12% | ₩50.84 Billion | ₩101.44 Billion | +8.19pp |
| 2017-12-31 | 41.93% | ₩24.37 Billion | ₩58.14 Billion | -23.30pp |
| 2016-12-31 | 65.22% | ₩23.11 Billion | ₩35.43 Billion | +24.66pp |
| 2015-12-31 | 40.57% | ₩7.50 Billion | ₩18.49 Billion | -7.13pp |
| 2014-12-31 | 47.70% | ₩6.90 Billion | ₩14.47 Billion | -- |